Immunome, Inc. (IMNM)
After hours:
| Previous close | 15.75 |
| Open | 15.75 |
| Bid | 15.41 x 100 |
| Ask | 15.49 x 200 |
| Day's range | 15.12 - 16.18 |
| 52-week range | 4.50 - 30.96 |
| Volume | |
| Avg. volume | 806,078 |
| Market cap | 926.725M |
| Beta (5Y monthly) | 1.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.38 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.33 |
Business WireImmunome Appoints Kinney Horn as Chief Business Officer
BOTHELL, Wash., May 02, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy.
ZacksAnalysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireImmunome Appoints Sandra M. Swain to Board of Directors
BOTHELL, Wash., April 25, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and has served on both public company and non-profit boards.
